Remedium Lifecare Q2 Profit Zooms 85% to Rs.8.62 Crore; Half-Year PAT Surges 6-Times YoY..
Varahi media.com online news,Mumbai, November 21, 2025: Small-cap pharma player Remedium Lifecare Limited delivered a blockbuster September quarter, with consolidated net profit nearly
Varahi media.com online news,Mumbai, November 21, 2025: Small-cap pharma player Remedium Lifecare Limited delivered a blockbuster September quarter, with consolidated net profit nearly doubling to ₹8.62 crore (₹862.34 lakh) – up a sharp 85.49% from ₹4.65 crore in the June quarter.
The company’s operational performance was equally impressive: EBITDA for Q2 FY26 jumped 82.7% sequentially to ₹10.44 crore, while revenue from operations soared to ₹111.06 crore.
Half-Year Highlights (H1 FY26)
- Revenue from operations: ₹224.42 crore
- Total income: ₹231.16 crore
- Profit After Tax: ₹13.27 crore (vs ₹2.13 crore PAT for entire FY25) – a stunning 6-fold jump
- EPS (H1 FY26): ₹0.15
- Total consolidated assets cross ₹1,623 crore as of September 30, 2025
Commenting on the results, Mr. Adarsh Munjal, Whole-Time Director, said, “These numbers are a testament to our operational discipline, successful business expansion, and efficient scaling of our specialty pharma and chemicals verticals. The momentum remains strong, and we are confident of sustaining this profitability trajectory through the rest of the financial year.”
The company has also bolstered its leadership and global ambitions:
- Appointed Mr. Rambhajan Vishwakarma and Mr. Vignesh Laxman Gawde to the Board for stronger governance and CDMO focus
- Incorporated a wholly-owned subsidiary in Singapore (September 2024) to accelerate international growth
- Aggressively expanding Contract Development & Manufacturing Organisation (CDMO) capabilities
With a robust balance sheet, expanding global footprint, and red-hot earnings growth, Remedium Lifecare is fast emerging as one of the most watched names in India’s specialty pharma and chemicals space.
About Author
